← Back to Search

Monoclonal Antibodies

LY3526318 for Osteoarthritis

Phase 2
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 8

Summary

This trial is testing a new medication called LY3526318 to see if it can help reduce knee pain in people with osteoarthritis. The study focuses on patients who suffer from chronic knee pain. Researchers want to find out if this new drug is safe and effective in improving knee function.

Eligible Conditions
  • Osteoarthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 8
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 8 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Change From Baseline for Worst Pain Intensity as Measured by NRS
Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)
Change From Baseline in Overall Improvement as Measured by Patient's Global Impression of Change
+7 more

Side effects data

From 2022 Phase 2 trial • 159 Patients • NCT05086289
3%
Headache
3%
Nausea
3%
Diarrhoea
3%
Dizziness
2%
Vomiting
2%
Somnolence
2%
COVID-19
2%
Fatigue
2%
Vaginal discharge*a
2%
SARS-CoV-2 test positive
1%
Flatulence
1%
Chest pain
1%
Chest discomfort
1%
Hip fracture
1%
Suicidal ideation
1%
Anaemia
1%
Constipation
1%
Abdominal distentation
1%
Abdominal pain
1%
Frequent bowel movements
1%
Restless legs syndrome
1%
Tension headache
1%
Upper respiratory tract infection
1%
Bronchitis
1%
Nasopharyngitis
1%
Urinary tract infection
1%
Concussion
1%
Dental restoration failure
1%
Post procedural complication
1%
Post procedural haematoma
1%
Pain
1%
Glucose tolerance impaired
1%
Hypertriglyceridaemia
1%
Musculoskeletal chest pain
1%
Tachycardia
1%
Immunisation reaction
1%
Insomnia
1%
Respiratory disorder
1%
Cataract operation
1%
Wisdom teeth removal
1%
Hypoacusis
1%
Photopsia
1%
Lipoma
100%
80%
60%
40%
20%
0%
Study treatment Arm
250 mg LY3526318 Week 1 to 4
Placebo Week 1 to 4
250 mg LY3526318/Placebo Week 5 to 8
Placebo Week 5 to 8

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3526318Experimental Treatment1 Intervention
Participants received 250 mg of LY3526318 orally, once daily for the first 4 weeks and were switched to placebo once daily for the next 4 weeks of the treatment period.
Group II: PlaceboPlacebo Group1 Intervention
Participants received placebo orally, once daily, for 8-weeks treatment period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3526318
2021
Completed Phase 2
~510

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,672 Previous Clinical Trials
3,463,633 Total Patients Enrolled
24 Trials studying Osteoarthritis
5,222 Patients Enrolled for Osteoarthritis
Study DirectorEli Lilly and Company
1,386 Previous Clinical Trials
426,538 Total Patients Enrolled
9 Trials studying Osteoarthritis
2,133 Patients Enrolled for Osteoarthritis
~39 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top